Royalty Report: Drugs, Cancer, Therapeutic – Collection: 2515

This agreement includes a non-exclusive grant by Licensee to Licensor.

The patents include Novel Method for the Production of anti-human Antigen Receptors and Uses thereof, and, Anti-EpCAM Immunoglobulins.

Decatumumab (MT201) is a recombinant human monoclonal antibody with a binding specificity to epithelial cell adhesion molecule (Ep-CAM). Adecatumumab (MT201) is being evaluated in two European Phase 2 clinical trials, one in patients with prostate cancer, and one in patients with metastatic breast cancer.

For the Screening license, Licensor grants a non-exclusive license under the Licensors Technology and Licensors interest in any Joint Know-How in the United States solely as necessary to carry out the Research hereunder during the Research Term.  Such license shall not be sublicensable.

For the Development and Commercialization license, Licensor grants an exclusive license, with the right to sublicense, under the Licensed Know-How and the Licensed Patents to generate and screen Licensees Mabs; and create Derivatives of Selected Mabs and Licensee Mabs, and develop, make, have made, use, sell, offer for sale, have sold, import and have imported Licensed Products for use in the Commercial Field in the Territory.

And, Licensor grants an exclusive license, with the right to sublicense, under the Licensed Know-How and the Licensed Patents to use the Selected Targets to generate and screen Licensee Mabs, and develop Licensed Mabs in the Commercial Field in the Territory during the Term.

Licensor Technology shall mean any Know-How that is and all Patents claiming inventions that are useful or necessary to generate and to screen Mabs binding to a Molecular Target, including without limitation methods of immunization, methods for maintaining and handling cell lines expressing Mabs, production and freezing media, and antibody screening facilitation tools including without limitation CellArrayâ„¢,  controlled by Licensor as of the effective date and during the term, and disclosed by Licensor to Licensee during the Term.

Joint Know-How shall mean any Know-How jointly invented by both Parties in the conduct of the Research, invented by Licensor in the conduct of the Research as a direct result of its use of Licensees Technology, or, invented by Licensee in the conduct of the Research as a direct result of its use of Licensors Technology.

Licensed Product shall mean any pharmaceutical product containing a Licensed Mab.

Cytotoxic Compound shall mean any Cytotoxic compound and all variants, fragments or derivatives thereof, whether produced by a botanical source, natural fermentation or chemical synthesis,  which is, in any case, controlled by Licensee.

Naked Mab Licensed Product shall mean any Licensed Product that is not a Cytotoxin-Coupled Licensed Product.

Antigen shall mean any protein, peptide or carbohydrate or other composition, and/or any fragment, peptide and/or epitope thereof which causes an immune response that produces antibodies.

The Commercial Field shall mean therapeutic products employing Mabs, alone or in conjunction with other ingredients, to treat cancer in humans.

Licensor grants a nonexclusive research and development license for Licensee to practice the use of Licensor' s cancer vaccines identified in the Licensor Patents and the antigens which they contain, to the extent that Licensor has a Valid Claim on any antigens included in any or all vaccines.

Biological Material shall mean human blood and lymphocytes obtained from patients enrolled in the Participating Licensor Clinical Trials.

The patents include
Ganglioside-KLH Conjugate Vaccines Plus QS21;
Synthesis of glycoconjugates of the globo-h epitope and uses thereof;
Synthesis Of The Breast Tumor-Associated Antigen Defined By Monoclonal Antibody MBR-1 And Uses Thereof;
Polyvalent Conjugate Vaccine for Cancer; and,
Optimal Polyvalent Vaccine for Cancer.